Details:
LUT014 is a novel B-Raf inhibitor, small molecule drug which is applied topically on the skin. It is being evaluated for the treatment of EGFRI-Induced Acneiform Rash.
Lead Product(s): LUT-014
Therapeutic Area: Dermatology Product Name: LUT014
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
BX001 is a topical gel formulation of a cocktail of naturally-occurring phage designed to improve the appearance of acne-prone skin by targeting Cutibacterium acnes (C. acnes), which are bacteria implicated in the pathophysiology of acne vulgaris.
Lead Product(s): BX001
Therapeutic Area: Dermatology Product Name: BX001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2021
Details:
The trial will evaluate the efficacy and safety of two strengths of LUT014 Gel, 0.03% or 0.10%, applied once daily for 4 weeks, compared to placebo, in patients with mCRC who develop Grade 2 EGFR inhibitor-induced acneiform lesions, with a 4-week follow up period.
Lead Product(s): LUT-014
Therapeutic Area: Dermatology Product Name: LUT014
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2021
Details:
ALLO-501A, a next-generation anti-CD19 AlloCAR T , eliminates the rituximab recognition domains in ALLO-501, which could allow for use in a broader patient population, including NHL patients with recent rituximab exposure.
Lead Product(s): LUT-014
Therapeutic Area: Dermatology Product Name: LUT014
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2021